Introduktion
Den här sidan ger en omfattande analys av den kända insiderhandelshistoriken för Jaime Contreras. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. Det är olagligt för insiders att göra affärer i sina företag baserat på specifik, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4. Trots dessa restriktioner tyder akademisk forskning på att insiders – i allmänhet – tenderar att överträffa marknaden i sina egna företag.
Genomsnittlig handelslönsamhet
Den genomsnittliga handelslönsamheten är den genomsnittliga avkastningen av alla köp på den öppna marknaden som insidern gjort under de senaste tre åren. För att beräkna detta undersöker vi alla oplanerade köp på öppen marknad som görs av insidern, exklusive alla affärer som markerats som en del av en 10b5-1-handelsplan. Vi beräknar sedan den genomsnittliga prestandan för dessa affärer under 3, 6 och 12 månader, med ett genomsnitt av var och en av dessa varaktigheter för att generera ett slutgiltigt resultatmått för varje affär. Slutligen tar vi ett genomsnitt av alla prestationsmått för att beräkna ett prestationsmått för insidern. Denna lista inkluderar endast insiders som har gjort minst tre affärer under de senaste två åren.
Om lönsamheten för denna insiderhandel är "N/A", så har insidern antingen inte gjort några köp på den öppna marknaden under de senaste tre åren, eller så är affärerna de har gjort för nya för att kunna beräkna ett tillförlitligt resultatmått.
Uppdateringsfrekvens: Dagligen
Företag med rapporterade insiderpositioner
SEC-anmälningarna visar att Jaime Contreras har rapporterat innehav eller affärer i följande företag:
Värdepapper | Titel | Senaste rapporterade innehav |
---|---|---|
US:ABT / Abbott Laboratories | Senior Vice President | 51 364 |
Hur man tolkar diagrammen
Följande diagram visar aktieutvecklingen för värdepapper efter varje icke-planerad handel på öppen marknad som görs av Jaime Contreras. Icke-planerad handel är affärer som inte gjordes som en del av en 10b5-1-handelsplan. Aktieutvecklingen visas som kumulativ procentuell förändring av aktiekursen. Till exempel, om en insiderhandel gjordes den 1 januari 2019, kommer diagrammet att visa den dagliga procentuella förändringen av värdepapperet fram till idag. Om aktiekursen skulle gå från $10 till $15 under denna tid, skulle den kumulativa procentuella förändringen i aktiekursen vara 50%. En förändring i priset från 10 USD till 20 USD skulle vara 100 % och en prisändring på 10 USD till 5 USD skulle vara -50 %.
I slutändan försöker vi avgöra hur nära insiders affärer korrelerar med överavkastning (positiv eller negativ) i aktiekursen för att se om insidern tar tid för sina affärer att dra nytta av insiderinformation. Tänk på situationen där en insider gjorde detta. I den här situationen förväntar vi oss antingen (a) positiv avkastning efter köp eller (b) negativ avkastning efter försäljning. I fallet med (a) skulle KÖP-diagrammet visa en serie uppåtlutande kurvor, vilket indikerar positiv avkastning efter varje köptransaktion. I fallet med (b) skulle SALE-diagrammet visa en serie nedåtlutande kurvor, vilket indikerar negativ avkastning efter varje försäljningstransaktion.
Detta är dock inte tillräckligt för att dra slutsatser. Om till exempel aktiekursen i bolaget var i en icke-cyklisk stigning under många år, skulle vi förvänta oss att alla tomter efter köpet skulle vara uppåtlutande. Likaså skulle icke-cykliska nedgångar under många år resultera i nedåtlutande post-trade tomter. Inget av dessa diagram skulle tyda på insiderhandel.
Den starkaste indikatorn skulle vara en situation där aktiekursen var extremt cyklisk, och det fanns både positiva signaler i KÖP-diagrammet och negativa plotter på SALE-diagrammet. Denna situation skulle i hög grad tyda på en insider som tog tid för affärer till sin ekonomiska fördel.
Insiderhandelshistorik
Den här tabellen visar den fullständiga listan över insideraffärer gjorda av Jaime Contreras som avslöjats för Securities Exchange Commission (SEC).
Fildatum | Transaktionsdatum | Schema | Ticker | Värdepapper | Kode | Aktier | Återstående aktier | Procentuell förandring | Aktie pris |
Transaktionsvärde | Återstående värde |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2020-04-23 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −25 681 | 51 364 | −33,33 | ||||
2020-04-23 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −36 715 | 36 715 | −50,00 | ||||
2020-04-23 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −46 016 | 0 | −100,00 | ||||
2020-04-23 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −83 226 | 62 205 | −57,23 | 98,00 | −8 156 148 | 6 096 090 | |
2020-04-23 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 25 681 | 145 431 | 21,45 | 75,90 | 1 949 188 | 11 038 213 | |
2020-04-23 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 36 715 | 119 750 | 44,22 | 59,94 | 2 200 697 | 7 177 815 | |
2020-04-23 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 46 016 | 83 035 | 124,30 | 44,40 | 2 043 110 | 3 686 754 | |
2020-04-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −343 | 2 624 | −11,56 | 79,34 | −27 214 | 208 188 | |
2020-04-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 740 | 2 967 | 33,23 | ||||
2020-03-03 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 001 | 37 019 | −5,13 | 77,89 | −155 858 | 2 883 410 | |
2020-03-03 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −6 936 | 39 020 | −15,09 | 79,19 | −549 262 | 3 089 994 | |
2020-02-25 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
A - Award | 68 578 | 68 578 | |||||
2020-02-25 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 11 250 | 45 956 | 32,42 | ||||
2019-04-29 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −80 860 | 0 | −100,00 | ||||
2019-04-29 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −57 962 | 57 604 | −50,15 | 78,11 | −4 527 412 | 4 499 448 | |
2019-04-29 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 80 860 | 115 566 | 232,99 | 38,40 | 3 105 024 | 4 437 734 | |
2019-04-29 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −36 716 | 73 430 | −33,33 | ||||
2019-04-29 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −46 016 | 46 016 | −50,00 | ||||
2019-04-29 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −12 332 | 34 706 | −26,22 | 70,02 | −863 487 | 2 430 114 | |
2019-04-29 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −70 400 | 47 038 | −59,95 | 70,00 | −4 928 000 | 3 292 660 | |
2019-04-29 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 36 716 | 117 438 | 45,48 | 59,94 | 2 200 757 | 7 039 234 | |
2019-04-29 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 46 016 | 80 722 | 132,59 | 44,40 | 2 043 110 | 3 584 057 | |
2019-04-24 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −918 | 2 227 | −29,19 | 73,12 | −67 124 | 162 838 | |
2019-04-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −385 | 3 145 | −10,91 | 79,94 | −30 777 | 251 411 | |
2019-04-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 935 | 3 530 | 36,03 | ||||
2019-03-04 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −8 726 | 103 446 | −7,78 | 78,28 | −683 045 | 8 097 443 | |
2019-03-04 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −402 | 112 172 | −0,36 | 78,28 | −31 469 | 8 780 824 | |
2019-03-04 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −600 | 112 574 | −0,53 | 78,28 | −46 969 | 8 812 405 | |
2019-03-04 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 333 | 113 174 | −1,16 | 78,29 | −104 357 | 8 860 053 | |
2019-03-04 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −300 | 114 507 | −0,26 | 78,29 | −23 487 | 8 964 753 | |
2019-03-04 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −600 | 114 807 | −0,52 | 78,30 | −46 978 | 8 989 044 | |
2019-03-04 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −100 | 115 407 | −0,09 | 78,30 | −7 830 | 9 036 368 | |
2019-03-04 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −300 | 115 507 | −0,26 | 78,30 | −23 490 | 9 044 314 | |
2019-03-04 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −200 | 115 807 | −0,17 | 78,31 | −15 661 | 9 068 499 | |
2019-03-04 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −9 992 | 116 007 | −7,93 | 77,23 | −771 682 | 8 959 221 | |
2019-02-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
A - Award | 77 045 | 77 045 | |||||
2019-02-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 14 698 | 125 999 | 13,21 | ||||
2019-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −77 550 | 80 860 | −48,96 | ||||
2019-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −62 600 | 0 | −100,00 | ||||
2019-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −108 090 | 111 301 | −49,27 | 71,68 | −7 747 891 | 7 978 056 | |
2019-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 77 550 | 231 798 | 50,28 | 38,40 | 2 977 920 | 8 901 043 | |
2019-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 62 600 | 154 248 | 68,30 | 47,00 | 2 942 200 | 7 249 656 | |
2019-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −83 951 | 62 600 | −57,28 | ||||
2019-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −84 169 | 158 410 | −34,70 | ||||
2019-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −46 017 | 92 032 | −33,33 | ||||
2019-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −177 457 | 91 648 | −65,94 | 70,00 | −12 421 990 | 6 415 360 | |
2019-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 83 951 | 269 105 | 45,34 | 47,00 | 3 945 697 | 12 647 935 | |
2019-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 84 169 | 185 154 | 83,35 | 38,40 | 3 232 090 | 7 109 914 | |
2019-02-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 46 017 | 100 985 | 83,72 | 44,40 | 2 043 155 | 4 483 734 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −10 200 | 54 968 | −15,65 | 66,87 | −682 074 | 3 675 710 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −474 | 73 043 | −0,64 | 66,86 | −31 694 | 4 884 020 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −14 800 | 73 517 | −16,76 | 66,86 | −989 528 | 4 915 347 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −840 | 88 317 | −0,94 | 66,86 | −56 158 | 5 904 433 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −8 335 | 89 157 | −8,55 | 66,85 | −557 195 | 5 960 145 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −805 | 97 492 | −0,82 | 66,84 | −53 810 | 6 516 853 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −4 116 | 98 297 | −4,02 | 66,84 | −275 113 | 6 570 171 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −928 | 102 413 | −0,90 | 66,84 | −62 023 | 6 844 773 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −200 | 103 341 | −0,19 | 66,82 | −13 365 | 6 905 762 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 799 | 103 541 | −1,71 | 66,82 | −120 209 | 6 918 610 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −600 | 105 340 | −0,57 | 66,82 | −40 089 | 7 038 292 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 900 | 105 940 | −2,66 | 66,81 | −193 749 | 7 077 851 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 463 | 108 840 | −2,21 | 66,80 | −164 541 | 7 271 056 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 505 | 111 303 | −2,20 | 66,80 | −167 334 | 7 435 040 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 768 | 113 080 | −2,39 | 66,80 | −184 889 | 7 553 179 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −8 895 | 116 576 | −7,09 | 66,79 | −594 097 | 7 786 111 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 640 | 125 471 | −1,29 | 66,78 | −109 527 | 8 379 581 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −112 668 | 0 | −100,00 | ||||
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −59 800 | 0 | −100,00 | ||||
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 200 | 127 111 | −1,70 | 66,78 | −146 916 | 8 488 473 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −800 | 129 311 | −0,61 | 66,78 | −53 420 | 8 634 742 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −58 993 | 130 111 | −31,20 | 66,77 | −3 938 963 | 8 687 511 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −690 | 189 104 | −0,36 | 66,76 | −46 068 | 12 625 529 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 100 | 189 794 | −1,09 | 66,76 | −140 196 | 12 670 647 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −100 | 191 894 | −0,05 | 66,76 | −6 676 | 12 809 884 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 400 | 191 994 | −0,72 | 66,75 | −93 450 | 12 815 600 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 900 | 193 394 | −0,97 | 66,74 | −126 816 | 12 908 083 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 000 | 195 294 | −0,51 | 66,74 | −66 740 | 13 033 922 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −500 | 196 294 | −0,25 | 66,74 | −33 368 | 13 099 680 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 400 | 196 794 | −0,71 | 66,73 | −93 422 | 13 132 064 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 000 | 198 194 | −0,50 | 66,72 | −66 720 | 13 223 504 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 200 | 199 194 | −1,09 | 66,72 | −146 773 | 13 289 228 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −900 | 201 394 | −0,44 | 66,71 | −60 039 | 13 434 994 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −110 | 202 294 | −0,05 | 66,70 | −7 338 | 13 494 021 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 900 | 202 404 | −0,93 | 66,70 | −126 730 | 13 500 347 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −800 | 204 304 | −0,39 | 66,70 | −53 356 | 13 626 055 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −600 | 205 104 | −0,29 | 66,69 | −40 014 | 13 678 386 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 300 | 205 704 | −1,11 | 66,68 | −153 376 | 13 717 371 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 500 | 208 004 | −0,72 | 66,68 | −100 020 | 13 869 707 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 300 | 209 504 | −0,62 | 66,68 | −86 678 | 13 968 679 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −600 | 210 804 | −0,28 | 66,67 | −40 002 | 14 054 303 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 400 | 211 404 | −1,12 | 66,66 | −159 996 | 14 093 248 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 501 | 213 804 | −0,70 | 66,66 | −100 057 | 14 252 175 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 500 | 215 305 | −1,15 | 66,66 | −166 638 | 14 351 155 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 100 | 217 805 | −0,95 | 66,65 | −139 965 | 14 516 703 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −699 | 219 905 | −0,32 | 66,64 | −46 585 | 14 655 569 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 300 | 220 604 | −1,03 | 66,64 | −153 272 | 14 701 051 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 112 668 | 222 904 | 102,21 | 39,12 | 4 407 572 | 8 720 004 | |
2018-08-31 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 59 800 | 110 236 | 118,57 | 34,94 | 2 089 412 | 3 851 646 | |
2018-04-25 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −849 | 2 595 | −24,65 | 59,36 | −50 397 | 154 039 | |
2018-04-03 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −342 | 3 444 | −9,03 | 59,92 | −20 493 | 206 364 | |
2018-04-03 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 1 376 | 3 786 | 57,10 | ||||
2018-03-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −4 900 | 50 436 | −8,85 | 60,00 | −294 000 | 3 026 160 | |
2018-03-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 384 | 55 336 | −2,44 | 58,80 | −81 381 | 3 253 812 | |
2018-03-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −8 649 | 56 720 | −13,23 | 60,55 | −523 697 | 3 434 396 | |
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
A - Award | 110 146 | 110 146 | |||||
2018-02-21 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 20 030 | 65 369 | 44,18 | ||||
2017-09-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −22 000 | 0 | −100,00 | ||||
2017-09-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −17 300 | 0 | −100,00 | ||||
2017-09-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −13 400 | 0 | −100,00 | ||||
2017-09-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 200 | 45 339 | −2,58 | 52,04 | −62 449 | 2 359 487 | |
2017-09-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 200 | 46 539 | −2,51 | 52,04 | −62 448 | 2 421 890 | |
2017-09-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −500 | 47 739 | −1,04 | 52,03 | −26 015 | 2 483 860 | |
2017-09-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −200 | 48 239 | −0,41 | 52,02 | −10 405 | 2 509 634 | |
2017-09-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 600 | 48 439 | −3,20 | 52,02 | −83 232 | 2 519 797 | |
2017-09-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −3 816 | 50 039 | −7,09 | 52,01 | −198 470 | 2 602 528 | |
2017-09-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 109 | 53 855 | −2,02 | 52,00 | −57 668 | 2 800 460 | |
2017-09-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −909 | 54 964 | −1,63 | 51,99 | −47 259 | 2 857 578 | |
2017-09-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 913 | 55 873 | −3,31 | 51,98 | −99 438 | 2 904 279 | |
2017-09-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 701 | 57 786 | −2,86 | 51,97 | −88 401 | 3 003 138 | |
2017-09-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −4 152 | 59 487 | −6,52 | 51,96 | −215 738 | 3 090 945 | |
2017-09-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −34 400 | 63 639 | −35,09 | 51,95 | −1 787 080 | 3 306 046 | |
2017-09-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 22 000 | 98 039 | 28,93 | 27,03 | 594 739 | 2 650 347 | |
2017-09-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 17 300 | 76 039 | 29,45 | 22,39 | 387 380 | 1 702 658 | |
2017-09-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 13 400 | 58 739 | 29,56 | 26,19 | 350 918 | 1 538 251 | |
2017-04-04 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −767 | 2 410 | −24,14 | 44,64 | −34 240 | 107 585 | |
2017-04-04 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −375 | 3 177 | −10,56 | 44,55 | −16 706 | 141 535 | |
2017-04-04 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 1 126 | 3 552 | 46,41 | ||||
2017-03-24 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
G - Gift | 394 | 64 297 | 0,62 | ||||
2017-03-24 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
G - Gift | −394 | 45 339 | −0,86 | ||||
2017-03-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −3 055 | 45 733 | −6,26 | 45,01 | −137 506 | 2 058 442 | |
2017-03-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −10 100 | 48 788 | −17,15 | 45,02 | −454 652 | 2 196 192 | |
2017-03-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −8 740 | 58 888 | −12,92 | 45,46 | −397 320 | 2 677 048 | |
2017-02-22 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
A - Award | 138 049 | 138 049 | |||||
2017-02-22 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 19 961 | 67 628 | 41,88 | ||||
2016-04-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −138 | 2 426 | −5,38 | 41,78 | −5 766 | 101 368 | |
2016-04-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −162 | 2 564 | −5,94 | 41,78 | −6 769 | 107 137 | |
2016-04-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −162 | 2 726 | −5,61 | 41,78 | −6 769 | 113 904 | |
2016-04-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −212 | 2 888 | −6,84 | 41,65 | −8 830 | 120 285 | |
2016-04-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 1 406 | 3 100 | 83,00 | ||||
2016-03-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 500 | 47 667 | −3,05 | 38,95 | −58 420 | 1 856 487 | |
2016-03-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −9 017 | 49 167 | −15,50 | 38,94 | −351 095 | 1 914 415 | |
2016-03-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −100 | 58 184 | −0,17 | 38,94 | −3 894 | 2 265 394 | |
2016-03-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −6 283 | 58 284 | −9,73 | 39,52 | −248 304 | 2 303 384 | |
2016-02-23 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
A - Award | 242 579 | 242 579 | |||||
2016-02-23 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 27 669 | 64 567 | 74,99 | ||||
2016-02-17 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −254 | 1 694 | −13,04 | 37,86 | −9 618 | 64 143 | |
2016-02-17 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −146 | 1 948 | −6,97 | 37,13 | −5 421 | 72 329 | |
2015-04-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −228 | 2 094 | −9,82 | 46,43 | −10 586 | 97 227 | |
2015-04-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −99 | 2 322 | −4,09 | 47,08 | −4 661 | 109 320 | |
2015-04-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 1 042 | 2 421 | 75,56 | ||||
2015-03-03 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −9 209 | 36 898 | −19,97 | 47,34 | −435 954 | 1 746 751 | |
2015-03-03 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −4 826 | 46 107 | −9,48 | 47,61 | −229 766 | 2 195 154 | |
2015-02-24 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
A - Award | 146 551 | 146 551 | |||||
2015-02-24 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 20 797 | 50 933 | 69,01 | ||||
2015-02-18 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −423 | 1 379 | −23,47 | 46,26 | −19 568 | 63 793 | |
2015-02-18 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −98 | 1 802 | −5,16 | 46,09 | −4 517 | 83 054 | |
2015-02-18 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −146 | 1 900 | −7,14 | 46,09 | −6 729 | 87 571 | |
2014-11-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −17 700 | 0 | −100,00 | ||||
2014-11-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −33 900 | 0 | −100,00 | ||||
2014-11-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 400 | 30 136 | −4,44 | 44,09 | −61 727 | 1 328 726 | |
2014-11-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −255 | 31 536 | −0,80 | 44,09 | −11 243 | 1 390 422 | |
2014-11-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 064 | 31 791 | −3,24 | 44,08 | −46 901 | 1 401 347 | |
2014-11-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −300 | 32 855 | −0,90 | 44,07 | −13 222 | 1 448 018 | |
2014-11-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −200 | 33 155 | −0,60 | 44,07 | −8 814 | 1 461 207 | |
2014-11-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −35 607 | 33 355 | −51,63 | 44,07 | −1 569 236 | 1 469 988 | |
2014-11-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −11 374 | 68 962 | −14,16 | 44,07 | −501 252 | 3 039 155 | |
2014-11-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −300 | 80 336 | −0,37 | 44,06 | −13 218 | 3 539 684 | |
2014-11-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 100 | 80 636 | −1,35 | 44,06 | −48 466 | 3 552 822 | |
2014-11-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 17 700 | 81 736 | 27,64 | 26,02 | 460 466 | 2 126 362 | |
2014-11-26 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 33 900 | 64 036 | 112,49 | 26,70 | 905 038 | 1 709 588 | |
2014-11-12 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −3 200 | 0 | −100,00 | ||||
2014-11-12 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −3 100 | 0 | −100,00 | ||||
2014-11-12 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −1 100 | 2 046 | −34,97 | 43,69 | −48 056 | 89 384 | |
2014-11-12 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −400 | 3 146 | −11,28 | 43,68 | −17 474 | 137 433 | |
2014-11-12 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −600 | 3 546 | −14,47 | 43,68 | −26 210 | 154 900 | |
2014-11-12 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −4 200 | 4 146 | −50,32 | 43,68 | −183 460 | 181 101 | |
2014-11-12 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 3 200 | 8 346 | 62,18 | 26,70 | 85 431 | 222 816 | |
2014-11-12 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 3 100 | 5 146 | 151,52 | 25,76 | 79 842 | 132 538 | |
2014-11-12 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
I - Other | −16 | 0 | −100,00 | 41,75 | −668 | ||
2014-04-02 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 979 | 2 046 | 91,75 | ||||
2014-03-04 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −600 | 30 136 | −1,95 | 39,38 | −23 630 | 1 186 876 | |
2014-03-04 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 000 | 30 736 | −6,11 | 39,38 | −78 762 | 1 210 414 | |
2014-03-04 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −650 | 32 736 | −1,95 | 39,37 | −25 590 | 1 288 816 | |
2014-03-04 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −4 831 | 33 386 | −12,64 | 39,37 | −190 177 | 1 314 273 | |
2014-03-04 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −3 919 | 38 217 | −9,30 | 39,79 | −155 937 | 1 520 654 | |
2014-02-25 |
|
4 | ABT |
ABBOTT LABORATORIES
Option(right to buy) |
A - Award | 112 668 | 112 668 | |||||
2014-02-25 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
A - Award | 18 403 | 42 136 | 77,54 | ||||
2014-02-19 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −621 | 1 067 | −36,79 | 38,96 | −24 191 | 41 565 | |
2014-02-19 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −126 | 1 688 | −6,95 | 38,81 | −4 890 | 65 511 | |
2014-02-19 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −101 | 1 814 | −5,27 | 38,81 | −3 920 | 70 401 | |
2014-02-19 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
F - Taxes | −151 | 1 915 | −7,31 | 38,81 | −5 860 | 74 321 | |
2013-11-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −2 715 | 0 | −100,00 | ||||
2013-11-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −1 545 | 0 | −100,00 | ||||
2013-11-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Option (right to buy) |
M - Exercise | −21 108 | 0 | −100,00 | ||||
2013-11-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −2 715 | 2 066 | −56,79 | 37,01 | −100 485 | 76 465 | |
2013-11-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 2 715 | 4 781 | 131,41 | 35,08 | 95 242 | 167 717 | |
2013-11-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
S - Sale | −22 653 | 23 733 | −48,84 | 36,83 | −834 231 | 874 003 | |
2013-11-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 1 545 | 46 386 | 3,45 | 35,08 | 54 199 | 1 627 221 | |
2013-11-01 |
|
4 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
M - Exercise | 21 108 | 44 841 | 88,94 | 33,37 | 704 374 | 1 496 344 | |
2013-09-26 | 3 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
23 733 | ||||||||
2013-09-26 | 3 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
20 | ||||||||
2013-09-26 | 3 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
63 903 | ||||||||
2013-09-26 | 3 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
2 066 | ||||||||
2013-09-26 | 3 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
16 | ||||||||
2013-09-26 | 3 | ABT |
ABBOTT LABORATORIES
Common shares without par value |
12 081 |